Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Twombly
Renee
R
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018849:Controlled Clinical Trials as Topic / Q000379:methods; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D032984:Ethics, Research; D005260:Female; D006801:Humans; D000077289:Letrozole; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole